This week we spoke to George Tziras, the new CEO of Small Pharma, about the company’s pipeline and priorities against the backdrop of a challenging economic context. The London-based psychedelic drug developer is almost exclusively focused on the short-acting psychedelic DMT, with its lead candidate (SPL026) designed to be administered alongside talk therapy for the treatment of Major Depressive…


Previous articleCombating Suicidality: A Role for Psilocybin and Ayahuasca?
Next articleKetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers